Clarius Group LLC Sells 41,000 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Clarius Group LLC cut its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 10.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 368,995 shares of the company's stock after selling 41,000 shares during the quarter. Clarius Group LLC owned approximately 0.25% of Denali Therapeutics worth $5,016,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Denali Therapeutics by 7.6% in the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock valued at $244,993,000 after purchasing an additional 843,996 shares during the period. FMR LLC lifted its stake in shares of Denali Therapeutics by 2.4% in the 4th quarter. FMR LLC now owns 8,019,746 shares of the company's stock valued at $163,442,000 after purchasing an additional 188,368 shares during the period. Alliancebernstein L.P. lifted its stake in shares of Denali Therapeutics by 8.8% in the 4th quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company's stock valued at $67,573,000 after purchasing an additional 268,378 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Denali Therapeutics by 6.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,058,615 shares of the company's stock valued at $62,335,000 after purchasing an additional 188,820 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Denali Therapeutics by 19.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company's stock valued at $37,805,000 after purchasing an additional 295,594 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Cantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. Robert W. Baird decreased their target price on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a research report on Thursday, May 8th. Oppenheimer decreased their target price on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Morgan Stanley began coverage on Denali Therapeutics in a research report on Friday, March 7th. They issued an "overweight" rating and a $33.00 target price for the company. Finally, B. Riley reaffirmed a "buy" rating and issued a $35.00 target price (down from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Denali Therapeutics presently has a consensus rating of "Buy" and an average price target of $33.71.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI traded down $0.20 during trading on Friday, hitting $13.89. 1,528,824 shares of the company were exchanged, compared to its average volume of 1,119,174. The company has a market cap of $2.02 billion, a PE ratio of -5.20 and a beta of 1.32. The stock has a 50 day moving average of $14.32 and a 200 day moving average of $17.44. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period in the previous year, the firm posted ($0.68) earnings per share. Sell-side analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.